Risk of second malignancy after cutaneous T-cell lymphoma

Kantor, Arlene F.; Curtis, Rochelle E.; Vonderheid, Eric C.; Scott, Edward M.; Fraumeni, Joseph F.

doi:10.1002/1097-0142(19890415)63:8<1612::aid-cncr2820630828>3.0.co;2-c

Cited by 95 publications

(89 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Factors that may have influenced reported rates of CL include the introduction of more sensitive methods of diagnosis (immunohistochemical and molecular techniques, such as Southern blot analysis and polymerase chain reaction), more precise diagnostic criteria and an increased public awareness of the need to seek early medical attention for skin lesions. The risk of CL increases after immunosuppression, including congenital immunodeficiency syndromes, exposure to immunosuppressive drugs and possibly after infection with the human immunodeficiency virus (HIV) (Kantor et al, 1989;Myskowski, 1991). Increased risk has also been postulated to be a result of direct occupational exposures, but studies are inconsistent in this regard (Tuyp et al, 1987;Whittemore et al, 1989).…”

mentioning

confidence: 99%

Cutaneous lymphoma in Israel, 1985-1993: a population-based incidence study

Iscovich

Paltiel²,

Azizi³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary The incidence rate of cutaneous lymphomas (CL) [including mycosis fungoides (MF) and non-mycosis fungoides (non-MF)] for the period 1985-93 in Israel was determined using data from the population-based Cancer Registry supplemented by a field survey that covered approximately 80% of lymphoma cases. After the field survey, corrected rates were 49% and 24% higher for MF and non-MF respectively (37% for CL overall). The age-adjusted incidence rates per 100 000 were 1.18 and 0.63 for Jewish men and women respectively. MF rates (0.77 in men and 0.35 in women) were higher than non-MF (0.41 and 0.28 respectively). Rates of CL were significantly lower in non-Jews. There were no significant differences in incidence among Jewish ethnic subgroups. However, the lack of variability in the incidence of these neoplasms among subpopulations is in contrast with findings for cutaneous malignant melanoma; the observed high rates of CL could, nonetheless, be consistent with the sunlight exposure hypothesis, operating perhaps through a different mechanism.

show abstract

mentioning

confidence: 99%

Cutaneous lymphoma in Israel, 1985-1993: a population-based incidence study

Iscovich

Paltiel²,

Azizi³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Cutaneous SCC has been reported on the forehead (n = 1) and ear (n = 2) [23], although no differences in propensity for head and neck cancers was reported compared to other cutaneous locations. Cancers have also been described in the trachea [2,10] and bronchus [8] as well as the larynx (n = 2) [8]. Kantor et al described a three-fold increase in the number of laryngeal second primary tumors in patients with MF [10].…”

Section: Resultsmentioning

confidence: 99%

“…Cancers have also been described in the trachea [2,10] and bronchus [8] as well as the larynx (n = 2) [8]. Kantor et al described a three-fold increase in the number of laryngeal second primary tumors in patients with MF [10]. Finally, Huang et al included a report of a germinoma of the thymus in their analysis of second malignant neoplasms in patients with MF as well as two "endocrine" tumors [8].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Mycosis Fungoides and Head and Neck Malignancies

Hull

Arsalan²,

Karakla³

2013

Journal of Case Reports in Medicine

View full text Add to dashboard Cite

Mycosis fungoides is a cutaneous T-cell lymphoma characterized by cutaneous patches and plaques that may progress to hematologic involvement and Sezary syndrome. Second primary tumors have been described in the literature without emphasis on head and neck neoplasms. We report two cases of head and neck malignancies in patients with a history of mycosis fungoides. A PubMed literature search was performed and results were reviewed. Second primary tumors in the head and neck have been reported in the nose and nasal cavity, sinuses, oral cavity, pharynx, hypopharynx, larynx, tracheobronchial tree, thymus, and skin. We present cases of submandibular mucoepidermoid carcinoma and papillary thyroid carcinoma in patients with a history of mycosis fungoides. Mycosis fungoides may confer increased risk of developing a second primary neoplasm of the head and neck. Possible mechanisms may include immunosuppression inherent in treatment modalities, the disease course of mycosis fungoides, or related genetic mutations.

show abstract

“…Indeed, the sensitivity and specificity of the glucose breath test in detecting SIBO are 62% and 83% compared with 66% and 44% of the lactulose breath test. 4 In psoriatic patients with SIBO, the eradication treatment improved the cutaneous manifestations in terms of both PASI and erythema colorimetric values. Before the treatment with rifaximin, in the three psoriasis patients who were positive for SIBO, the erythema colorimetric values were 17, 15, and 18 and the PASI scores were 18, 16, and 15, respectively; after the eradication of SIBO, the erythema colorimetric values were 10, 10, and 11 and the PASI scores were 16, 15, and 12, respectively.…”

mentioning

confidence: 99%

Psoriasis and small intestine bacterial overgrowth

et al. 2017

View full text Add to dashboard Cite

Correspondence Psoriasis and small intestine bacterial overgrowthIn psoriasis, the alteration of intestinal microbiota that characterizes the syndrome of small intestinal bacterial overgrowth (SIBO) may influence the immune homeostasis determining one proinflammatory status. 1 In subjects with psoriasis, we investigated the prevalence of SIBO and its possible influence on the clinical course of the disease, especially on the inflammatory component of the psoriatic plaques.Thirty patients with psoriasis (14 women and 16 men, mean age 39 years) were recruited and studied prospectively. Clinically, they showed active psoriatic manifestations resistant to topical and systemic medications. They had no history of bowel diseases. All patients underwent a dermatological examination to assess: (1) type of psoriasis (plaque, guttate, inverse, erythrodermic); (2) psoriasis severity (mild, moderate, severe) using the Psoriasis Area Severity Index (PASI); (3) severity of the erythema in the psoriatic plaques as evaluated by the colorimeter ChromaMeter CR200 (Minolta, Milano). The skin was considered inflamed when the colorimetric values were ≥12.Subsequently, after suitable preparation, the patients were subjected to a glucose breath test (GBT) to investigate the presence of SIBO. Whenever the test was positive, the patient was treated with rifaximin (1200 mg/day for 12 days) in combination with partially hydrolyzed guar gum (GG) (5 g/day). In fact, the combination of rifaximin with partially hydrolyzed GG, a prebiotic that can have a beneficial effect on intestinal motility, seems to be more useful in eradicating SIBO compared with rifaximin alone. 2 Moreover, rifaximin is similar to rifampin which, besides the antibacterial action, has been shown to be a biofilm-dispersing agent. 3The efficacy of the eradication therapy was evaluated with a new GBT a month later. Furthermore, all patients underwent another dermatological examination to evaluate the eradication effect on the skin by repeating the PASI and chromameter evaluation. A control group of 60 healthy volunteers was analyzed using the same procedure.The psoriatic skin had colorimetric values (mean 15.53 AE 1.97) significantly higher than the skin of healthy volunteers (mean 6.23 AE 2.00) (P < 0.001). The prevalence of SIBO in psoriatic patients (3 of 30, 10%) did not differ statistically from the control group (3 of 60, 5%) (P = 0.6). Rifaximin-GG treatment markedly improved the inflammation in the lesions of positive SIBO psoriatic patients compared with their nonlesional skin. More specifically, the erythema intensity was reduced by 43% in the three evaluated plaques. The GBT test performed after the antibiotic treatment in the three psoriasis patients with SIBO confirmed the efficacy of the eradication therapy in all cases.The prevalence of SIBO in patients with psoriasis is comparable to that in the control group. This is in contrast with a previous study that claimed SIBO prevalence to be higher in psoriatic however, the difference is not statistically significa...

show abstract

Risk of second malignancy after cutaneous T-cell lymphoma

Cited by 95 publications

References 24 publications

Cutaneous lymphoma in Israel, 1985-1993: a population-based incidence study

Cutaneous lymphoma in Israel, 1985-1993: a population-based incidence study

Mycosis Fungoides and Head and Neck Malignancies

Psoriasis and small intestine bacterial overgrowth

Contact Info

Product

Resources

About